Intellia Therapeutics, Inc.
A clinical-stage genome editing company developing therapeutics using CRISPR/Cas9.
NTLA | US
Overview
Corporate Details
- ISIN(s):
- US45826J1051
- LEI:
- Country:
- United States of America
- Address:
- 40 ERIE STREET, 2139 CAMBRIDGE
- Website:
- https://www.intelliatx.com/
Description
Intellia Therapeutics, Inc. is a clinical-stage genome editing company focused on developing potentially curative therapeutics for severe diseases using CRISPR/Cas9 technology. The company's strategy employs a full-spectrum approach, advancing both *in vivo* programs, where genetic editing occurs directly inside the body, and *ex vivo* programs, where cells are engineered outside the body and then administered to the patient. Its clinical pipeline targets a range of genetic disorders, with a key focus on conditions such as transthyretin (ATTR) amyloidosis. Intellia aims to create a new class of medicines by developing single-course treatments with the potential to permanently correct the underlying cause of a disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Intellia Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Intellia Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Intellia Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
